Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447078 · ClinicalTrials.gov registry record · Phase 3
Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection
A Phase 3 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
NCT05447078: Completed Phase 3 study, sponsored by University of Mississippi Medical Center.
NCT05447078 is a Phase 3 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 492 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447078, a Phase 3 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
Study Summary
This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
Primary Outcome
NK cell-mediated cytotoxicity is characterized by cytolysis of a CFSE-labeled target cell (K562) by effector cells (NK cells). Labeled K562 are cultured with NK cells for a period of time, then all cells labeled with a live-dead stain, 7-AAD. The cytolytic activity is expressed as the percent dead K562. Differences in cytolytic activity (% dead K562) from baseline to 20 weeks.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Immulina TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
What the finished NCT05447078 record still lists
NCT05447078 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05447078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05447078 about?
NCT05447078 is a clinical study titled "Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection". This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
What is the current status of trial NCT05447078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2022-07-01. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT05447078?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Immulina TM (DRUG).
Who is sponsoring clinical trial NCT05447078?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05447078's enrollment target sits among peer trials
492 780th of 2000 higher than 1,220 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI